Nothing Special   »   [go: up one dir, main page]

AU2001228825A1 - Remedies - Google Patents

Remedies

Info

Publication number
AU2001228825A1
AU2001228825A1 AU2001228825A AU2882501A AU2001228825A1 AU 2001228825 A1 AU2001228825 A1 AU 2001228825A1 AU 2001228825 A AU2001228825 A AU 2001228825A AU 2882501 A AU2882501 A AU 2882501A AU 2001228825 A1 AU2001228825 A1 AU 2001228825A1
Authority
AU
Australia
Prior art keywords
growth factor
nerve growth
factor production
enhancing
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228825A
Inventor
Suzu Deguchi
Ikunoshin Kato
Eiji Kobayashi
Tuo-Ping Li
Eiji Nishiyama
Hiromu Ohnogi
Hiroaki Sagawa
Masahiro Shiraga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Shuzo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Shuzo Co Ltd filed Critical Takara Shuzo Co Ltd
Publication of AU2001228825A1 publication Critical patent/AU2001228825A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a therapeutic agent or prophylactic agent for a disease that requires enhancement of nerve growth factor production, an enhancer for nerve growth factor production, or a food, beverage or feed for enhancing nerve growth factor production, each comprising as an effective ingredient a specified compound or a salt thereof having enhancing activity for nerve growth factor production; a method for enhancing nerve growth factor production, comprising administering to a mammal the above-mentioned compound or a salt thereof; and use of the above-mentioned compound or a salt thereof in the preparation of a therapeutic agent or prophylactic agent for a disease that requires enhancement of nerve growth factor production, an enhancer for nerve growth factor production, or a food, beverage or feed for enhancing nerve growth factor production. In addition, the present invention provides novel compounds having enhancing activity for nerve growth factor production.
AU2001228825A 2000-01-27 2001-01-26 Remedies Abandoned AU2001228825A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2000-19208 2000-01-27
JP2000-19331 2000-01-27
JP2000019331 2000-01-27
JP2000019208 2000-01-27
JP2000254683 2000-08-24
JP2000-254683 2000-08-24
JP2000-308519 2000-10-06
JP2000308519 2000-10-06
PCT/JP2001/000513 WO2001054682A1 (en) 2000-01-27 2001-01-26 Remedies

Publications (1)

Publication Number Publication Date
AU2001228825A1 true AU2001228825A1 (en) 2001-08-07

Family

ID=27480961

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228825A Abandoned AU2001228825A1 (en) 2000-01-27 2001-01-26 Remedies

Country Status (10)

Country Link
US (1) US7268160B2 (en)
EP (1) EP1254658B1 (en)
JP (1) JP4249926B2 (en)
KR (2) KR20060095786A (en)
CN (1) CN100346776C (en)
AT (1) ATE409028T1 (en)
AU (1) AU2001228825A1 (en)
DE (1) DE60135904D1 (en)
TW (1) TWI255181B (en)
WO (1) WO2001054682A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127572A3 (en) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Use of flavones for treating cycloxygenase-2 mediated diseases
TWI233353B (en) * 2000-04-11 2005-06-01 Takara Bio Inc Therapeutic or preventive agents containing polyphenols
FR2841784B1 (en) 2002-07-08 2007-03-02 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2EN-1-ONE DERIVATIVES, PREPARATION AND USES
FR2841900B1 (en) * 2002-07-08 2007-03-02 Genfit S A NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES
KR20050053731A (en) 2002-10-01 2005-06-08 다카라 바이오 가부시키가이샤 Remedies
WO2004043475A1 (en) * 2002-11-12 2004-05-27 Takara Bio Inc. Agent for improving learning and memorizing abilities
WO2004096198A1 (en) * 2003-05-02 2004-11-11 Takara Bio Inc. Therapeutic agent
EP1702912A4 (en) * 2003-12-05 2007-10-24 Takara Bio Inc Remedy
TW200539862A (en) * 2004-02-06 2005-12-16 Takara Bio Inc Remedy agent
JP2008542254A (en) * 2005-05-26 2008-11-27 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ Pharmaceutical composition useful for the treatment of hepatocellular carcinoma
JP2007230946A (en) * 2006-03-02 2007-09-13 Nagase & Co Ltd Neurite-extending agent
JP4912708B2 (en) * 2006-03-24 2012-04-11 三井農林株式会社 New substance TMR
JP5405460B2 (en) * 2007-07-25 2014-02-05 シムライズ アーゲー 3- (4-Hydroxy-3-methoxyphenyl) -1- (4-hydroxyphenyl) -1-propanone and its use as an antioxidant
CN102697757B (en) * 2012-05-18 2014-06-04 广州军区广州总医院 Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy
JP2017043572A (en) * 2015-08-28 2017-03-02 株式会社ファンケル Bdnf production promoter comprising helipyrone a as active ingredient
CN109651121B (en) * 2019-01-25 2021-11-26 陕西理工大学 Synthetic method of Robtein

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3761471A (en) * 1970-11-16 1973-09-25 Tamio Nishimura Benzalacetone or acetophenone amidinohydrazone derivatives and the production thereof
FI874163A (en) 1986-09-26 1988-03-27 Mitsui Toatsu Chemicals KATEKOLDERIVAT SAMT PREPARAT INNEHAOLLANDE DESAMMA FOER HAEMMANDE OCH BOTANDE AV REGRESSIVA SJUKDOMAR I DET CENTRALA NERVSYSTEMET.
US5234951A (en) 1986-12-12 1993-08-10 Tsumura Juntendo, Inc. Anti-ulcer agent comprising chalcone derivative
JPS6442422A (en) * 1987-08-10 1989-02-14 Tsumura & Co Antiulcer agent
KR890700117A (en) 1986-12-12 1989-03-02 쓰무라 아끼라 Anti-ulcer agents and novel chalcone derivatives containing chalcone derivatives as active ingredients
JPH01125320A (en) * 1987-11-09 1989-05-17 Tsumura & Co Testosterone-5alpha-reductase inhibitor
JPH02104568A (en) 1988-06-22 1990-04-17 Yoshitomi Pharmaceut Ind Ltd Acting agent of production promotion of nerve growth factor
JPH02187765A (en) * 1989-01-14 1990-07-23 Oki Electric Ind Co Ltd Material for photo-decolorable layer for enhancing contrast and pattern forming method with same
JPH08768B2 (en) 1989-08-24 1996-01-10 武田薬品工業株式会社 Nerve growth factor secretion inducer
JPH03122645A (en) * 1989-10-05 1991-05-24 Nippon Kanko Shikiso Kenkyusho:Kk Light absorptive material for photoresist
JP2719042B2 (en) 1990-11-22 1998-02-25 三共株式会社 Nerve growth factor production / secretion promoter
JPH07110812B2 (en) 1990-12-11 1995-11-29 財団法人喫煙科学研究財団 Nerve growth factor biosynthesis promoter
JPH0578384A (en) * 1991-03-27 1993-03-30 Taisho Pharmaceut Co Ltd Flavonol derivative
JPH0561220A (en) * 1991-08-30 1993-03-12 Ricoh Co Ltd Electrophotographic sensitive body
JPH05246932A (en) * 1992-03-04 1993-09-24 Nippon High Potsukusu:Kk 3,4-dihydroxycalcon derivative
JPH07194355A (en) * 1993-12-28 1995-08-01 Sanei Gen F F I Inc Ethanol preparation
JPH07285856A (en) * 1994-04-21 1995-10-31 Hoechst Japan Ltd Therapeutic agent for osteoporosis
JPH0827086A (en) 1994-07-22 1996-01-30 Sagami Chem Res Center N-acyl-n-substituted cinnamoyl ethylene diamine derivative
FR2747568B1 (en) 1996-04-17 1999-09-17 Oreal USE OF AT LEAST ONE LIPOXYGENASE INHIBITOR AND AT LEAST ONE CYCLO-OXYGENASE INHIBITOR FOR MODIFYING HAIR AND / OR HAIR GROWTH
JPH10114649A (en) 1996-10-15 1998-05-06 Dokutaazu Kosumeteikusu:Kk Improver for aqueous body fluid and composition for oral administration comprising the same
GB9712966D0 (en) 1997-06-19 1997-08-27 Indena Spa Novel chalcones
JPH11246398A (en) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd Prophylactic or therapeutic agent for disorder caused by increment of lipoperoxide in vivo
EP0998939A1 (en) * 1998-09-09 2000-05-10 The School Of Pharmacy, University Of London Chalcone plant extracts for use in therapy
AU2461200A (en) * 1999-02-19 2000-09-04 Takara Shuzo Co., Ltd. Remedies
AU3837300A (en) 1999-04-15 2000-11-02 Takara Shuzo Co., Ltd. Remedies
AU2300001A (en) 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease

Also Published As

Publication number Publication date
EP1254658A1 (en) 2002-11-06
CN100346776C (en) 2007-11-07
CN1419448A (en) 2003-05-21
DE60135904D1 (en) 2008-11-06
KR20060095786A (en) 2006-09-01
ATE409028T1 (en) 2008-10-15
TWI255181B (en) 2006-05-21
US7268160B2 (en) 2007-09-11
KR20020073186A (en) 2002-09-19
EP1254658B1 (en) 2008-09-24
EP1254658A4 (en) 2003-06-18
US20030144316A1 (en) 2003-07-31
JP4249926B2 (en) 2009-04-08
KR100711537B1 (en) 2007-04-27
WO2001054682A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
AU2001228825A1 (en) Remedies
EP1247456A3 (en) Palatable pharmaceutical compositions for companion animals
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP1232757A4 (en) Remedies for diseases in association with decrease in bone mass
BG105459A (en) Pharmaceutical moxifloxacin preparation
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2005030753A3 (en) Therapeutic agents useful for treating pain
EP1356811A4 (en) Preventives or remedies for arthritis
PL342614A1 (en) Anticarcinogenic drugs
CA2298645A1 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
WO2002070464A3 (en) Hydrazones and their therapeutic use
AU693833B2 (en) Products containing G-CSF and TNF binding protein
WO2001097793A3 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
WO2001072685A3 (en) Polyamine analogues as cytotoxic agents
EP1354584A4 (en) Preventives for arthritis
HK1085744A1 (en) Steroid compounds with anti-tumor activity
WO2001030328A3 (en) Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions
WO2002046163A3 (en) Quinoline derivatives and their use as anti-epileptics
EP1232748A4 (en) Substituted nitrobenzene derivatives as medicines and other useful uses thereof
WO2003029495A3 (en) Coniosulphides and their derivatives, method for their production and use as medicaments
AU2003267751A1 (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
UA74406C2 (en) a polysaccharide compound presenting immune stimulating activity, a process for its preparation, use and a pharmaceutical preparation based thereon